Exelixis | EXEL - Net Income



Exelixis reported $230.42M in Net Income for its fiscal quarter ending in July of 2025.


Net Income Change Date
Acadia Pharmaceuticals USD 26.67M 7.68M Jun/2025
Agios Pharmaceuticals USD -112020000 22.73M Jun/2025
Amgen USD 1.43B 298M Jun/2025
AstraZeneca USD 2.45B 466M Jun/2025
Bayer EUR -199000000 1.5B Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Cytokinetics USD -134370000 27.01M Jun/2025
Eisai JPY 14.47B 13.52B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Exelixis USD 230.42M 70.8M Jul/2025
Genmab DKK 336M 141M Jun/2025
Glaxosmithkline GBP 1.44B 1.03B Jun/2025
Incyte USD 405M 246.8M Jun/2025
Ionis Pharmaceuticals USD 123.55M 270.49M Jun/2025
MacroGenics USD -36250000 20.83M Jun/2025
Merck USD 4.43B 652M Jun/2025
Moderna USD -825000000 146M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Sanofi EUR 3.94B 3.44B Jun/2025
Takeda JPY 124.24B 227.4B Jun/2025
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
Xencor USD -30825000 17.59M Jun/2025